Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare hFSH-HP (Fostipur) and hMG-HP(Meriofert) in Patients With Polycystic Ovary Under a IVF/ICSI Cycle.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female age between 18 and 38 years (inclusive)~* Women with a BMI under 30 kg / m2~* Diagnosis of polycystic ovary syndrome (according to criteria of Rotterdam)~* Women who want pregnancy~* Basal basal FSH levels under or equal 10 IU / l~* Infertility justify treatment with in vitro fertilization / intracytoplasmic sperm injection~* To be included in a protocol with GnRH antagonist~* Presence of both ovaries and uterus able to support embryo implantation and pregnancy~* Absence of pregnancy before starting ovarian stimulation~* Written consent~Exclusion Criteria:~* Severe male factor not allowing an in vitro fertilization / intracytoplasmic sperm injection with ejaculated sample~* Patients with low ovarian reserve~* Important endocrine-metabolic systemic diseases affecting pituitary, thyroid, adrenals, pancreas, liver or kidney~* HIV seropositivity~* To have frozen embryos from previous cycles of assisted reproduction~* Undiagnosed vaginal haemorrhage~* Poor response in previous cycles of in vitro fertilization with standard stimulation protocols~* Pregnancy, lactation or contraindication to get pregnant~* Malformations of the sexual organs incompatible with pregnancy~* History of allergy to gonadotrophin preparations or its excipients~* Alcohol, drugs or psychotropic addiction~* Concurrent participation in another study~* Previous history of severe hyperstimulation syndrome~* Concomitant medication that may interfere with the study medication: different hormonal treatments used in the study, other thyroid hormones, antipsychotics, anxiolytics, hypnotics, sedatives, chronic treatment with inhibitors of prostaglandin

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 38 Years
- Healthy Volunteers: f

Study Arms:
- Fostipur (Type: ACTIVE_COMPARATOR): None
- Meriofert (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).